ASX Shareholder Claims

Proposed Class Action – Mesoblast Limited (ASX:MSB)

A shareholder class action has been commenced against Mesoblast Limited (“MSB”) in the Federal Court of Australia.

The action is being conducted by William Roberts Lawyers, on behalf of aggrieved MSB investors.


Claim Overview

The Class Action alleges that during the Relevant Period, Mesoblast engaged in unlawful conduct which misled the market about one of the company’s developmental stem cell therapies known as ‘Remestemcel-L’.


We consider that investors who acquired and held an interest in MSB shares during the Relevant Period (whether an interest in ASX-traded MSB shares or, a security that derived its value from ASX-traded MSB shares – together “MSB Security Holders“) have a reasonable basis to seek to recover from MSB the amount of losses they have suffered from the purchase of that interest.


ISIN: AU000000MSB8
Relevant Period: 22 February 2018 to 17 December 2020 (inclusive)
Shares traded in Period TBA


Class Members

MSB Security Holders who acquired their interest in ASX-traded MSB shares during the period 22 February 2018 to 17 December 2020 (inclusive).


I think I have a claim. How do I participate in the proposed class action?

Click on the “REGISTER” button below to register your expression of interest, to receive further information about the Class Action, including:

  • a Product Disclosure Statement in respect of the Scheme (which gives more information on the Class Action, the Scheme and on your rights and entitlements if you choose to participate);
  • how to participate; and
  • updates about the progress of the class action.


By registering your expression of interest, you are indicating your interest in receiving further information about the class action. Registering your expression of interest is not a commitment by any party to participate in funded litigation, nor is it an application to become a Class Member of member of the Scheme.

The Class Action is being funded and conducted as a litigation funding scheme, compliant with regulations introduced by the Australian Government in 2020. The name of the scheme is the Mesoblast Litigation Funding Scheme.

As the Scheme’s Responsible Entity, CASL Governance Ltd (CASL) is responsible for issuing the Scheme’s Product Disclosure Statement, as well as any interests in the Scheme.



*The information in this PDS is subject to change from time-to-time. Information that is not material information can be updated by CASL Goverance Ltd and is found here. Mesoblast Litigation Funding Scheme, ARSN 654 319 810.Responsible Entity for the Scheme is CASL Governance Ltd, ABN 97 643 977 833, AFSL No. 525889. ICP Funding Pty Ltd, ABN 32 626 526 458, Authorised Representative No. 1286235.